UNLABELLED: Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide which was originally isolated from ovine hypothalamus. PACAP exists in at least two biologically active forms, PACAP-38 and PACAP-27. The aim of this study was to establish the distribution, localization and smooth muscle effects of PACAP-38 and PACAP-27 in the human uteroplacental unit. For this purpose we used radioimmunoassay, immunocytochemistry and in vitro studies of the effect of the peptides on smooth muscle activity. RESULTS: By radioimmunoassay both peptides were detected throughout the uteroplacental unit. The concentrations of PACAP-27 were in general low, ranging from 1/6-1/25 of the corresponding PACAP-38 concentrations. PACAP-immunoreactivity was localized in nerve fibres of the lower segment of the pregnant uterus, but the number of PACAP-immunoreactive nerves was very clearly reduced compared to the corresponding isthmic region of non-pregnant myometrial tissue. PACAP-immunoreactive fibres were not observed in placenta or in the umbilical cord. Both PACAP-38 and PACAP-27 caused a concentration-dependent relaxation on stem villous arteries and on the intramyometrial arteries. Neither of the peptides displayed any effect on non-vascular smooth muscle specimens from the term pregnant myometrium. In conclusion the findings suggest a vasoregulator role of PACAP in the human uteroplacental unit.
UNLABELLED: Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide which was originally isolated from ovine hypothalamus. PACAP exists in at least two biologically active forms, PACAP-38 and PACAP-27. The aim of this study was to establish the distribution, localization and smooth muscle effects of PACAP-38 and PACAP-27 in the human uteroplacental unit. For this purpose we used radioimmunoassay, immunocytochemistry and in vitro studies of the effect of the peptides on smooth muscle activity. RESULTS: By radioimmunoassay both peptides were detected throughout the uteroplacental unit. The concentrations of PACAP-27 were in general low, ranging from 1/6-1/25 of the corresponding PACAP-38 concentrations. PACAP-immunoreactivity was localized in nerve fibres of the lower segment of the pregnant uterus, but the number of PACAP-immunoreactive nerves was very clearly reduced compared to the corresponding isthmic region of non-pregnant myometrial tissue. PACAP-immunoreactive fibres were not observed in placenta or in the umbilical cord. Both PACAP-38 and PACAP-27 caused a concentration-dependent relaxation on stem villous arteries and on the intramyometrial arteries. Neither of the peptides displayed any effect on non-vascular smooth muscle specimens from the term pregnant myometrium. In conclusion the findings suggest a vasoregulator role of PACAP in the human uteroplacental unit.
Authors: D Reglodi; J Gyarmati; T Ertl; R Borzsei; J Bodis; A Tamas; P Kiss; K Csanaky; E Banki; C Bay; J Nemeth; Z Helyes Journal: J Endocrinol Invest Date: 2010 Jul-Aug Impact factor: 4.256
Authors: R Brubel; A Boronkai; D Reglodi; B Racz; J Nemeth; P Kiss; A Lubics; G Toth; G Horvath; T Varga; D Szogyi; E Fonagy; J Farkas; A Barakonyi; Sz Bellyei; L Szereday; M Koppan; A Tamas Journal: J Mol Neurosci Date: 2010-05-07 Impact factor: 3.444
Authors: G Horvath; D Reglodi; R Brubel; M Halasz; A Barakonyi; A Tamas; E Fabian; B Opper; G Toth; M Cohen; L Szereday Journal: J Mol Neurosci Date: 2014-05-30 Impact factor: 3.444
Authors: Dora Reglodi; Andrea Tamas; Miklos Koppan; Donat Szogyi; Laura Welke Journal: Front Endocrinol (Lausanne) Date: 2012-12-11 Impact factor: 5.555